Since HDAC6 is overexpressed in CML stem cells and that its inhibition can potentially cause BCR-ABL degradation [68], this deacetylase appears as a strong candidate for CML treatment. Here, HDAC6 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.